Archiv
Archiv anzeigen:
bis


Voxelotor for Sickle Cell Disease

David Green, MD, PhD reviewing Howard J et al. Blood 2019 Jan 17

In a phase I/II study, voxelotor safely decreased hemolysis and red cell sickling in patients with mild disease.


Targeted vs. Immunotherapy for BRAF-Mutated Metastatic Melanoma

Sunandana Chandra, MD reviewing Pires da Silva I et al. Clin Cancer Res 2019 Jan 10

BRAFV600E- and BRAFV600K-mutated melanomas responded differently to the two types of therapy.


Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

David Green, MD, PhD reviewing Scully M et al. N Engl J Med 2019 Jan 9

Normalization of the platelet count was significantly faster with caplacizumab than with placebo.


Are Circulating Tumor Cells Predictive of Late Recurrence of ER-Positive Breast Cancer?

William J. Gradishar, MD reviewing Sparano J et al. JAMA Oncol 2018 Dec 1

The presence of CTCs 5 years after diagnosis was associated with a 13-fold higher risk for recurrence.


Minimally Invasive Surgery for Esophageal Cancer

David H. Ilson, MD, PhD reviewing Mariette C et al. N Engl J Med 2019 Jan 10

The rate of major complications was significantly lower with hybrid minimally invasive esophagectomy than with conventional transthoracic open esophagectomy.


Luspatercept for Beta-Thalassemia

David Green, MD, PhD reviewing Piga A et al. Blood 2019 Jan 7

Luspatercept increased hemoglobin and reduced transfusion burden in a phase II study.


Managing Patients with Low von Willebrand Factor Levels

David Green, MD, PhD reviewing Lavin M and O'Donnell JS. Blood 2018 Dec 21

Diagnosing and treating patients with VWF levels in the range of 30 to 50 IU/dL.


Screening Patients for Pancreatic Cancer: Making Some Progress

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Paiella S et al. Am J Gastroenterol 2018 Dec 11

Image-based screening detected pancreatic malignancies in some high-risk individuals.


Microsatellite Instability in Prostate Cancer and the Role of Immune Checkpoint Blockade

Robert Dreicer, MD, MS, MACP, FASCO reviewing Abida W et al. JAMA Oncol 2018 Dec 27, Reichert ZR et al. JAMA Oncol 2018 Dec 27

MSI may be a biomarker for checkpoint inhibitor response.


Adjuvant FOLFIRINOX vs. Gemcitabine for Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Conroy T et al. N Engl J Med 2018 Dec 20, Kindler HL. N Engl J Med 2018 Dec 20

FOLFIRINOX significantly improved survival but increased toxicity.


Archiv
Seite von 76
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.